All the news Showing 10 of 57 articles from: Antiviral therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Tenofovir alafenamide for hepatitis B shows improved kidney and bone safety after a year Liz Highleyman / 08 January 2019 Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ... Hepatitis B capsid assembly modulators show good antiviral activity Liz Highleyman / 21 December 2018 Experimental drugs that interfere with hepatitis B virus (HBV) capsid assembly continue to show promise as a new approach to antiviral treatment, according to research presented at the AASLD Liver Meeting last ... China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection Gilead press release / 20 November 2018 Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection Janssen press release / 05 October 2018 Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit Arrowhead / 07 September 2018 New simplified scoring system identifies people with hepatitis B in need of treatment in Africa Keith Alcorn / 02 July 2018 Liver enzyme and hepatitis B 'e' antigen test results are sufficient to determine which people with hepatitis B need antiviral treatment for the infection in sub-Saharan Africa, a study carried ... Switching to TAF improves safety in people with hepatitis B with kidney and bone risk factors Liz Highleyman / 04 May 2018 People with risk factors for tenofovir toxicity who switched from tenofovir disoproxil fumarate (TDF; Viread) to the new tenofovir alafenamide (TAF; Vemlidy) maintained hepatitis B virus (HBV) suppression and showed evidence of improved kidney and ... 'Virus-cracking' molecules advance fight against hepatitis B Science Daily / 07 February 2018 Treatment that interferes with viral assembly shows promise for hepatitis B Liz Highleyman / 18 December 2017 JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in ... RNA interference therapy lowers viral biomarker in people with hepatitis B Liz Highleyman / 14 December 2017 ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the ... ← First12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E NAFLD Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds